← All trials
NCT06343805
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2024
- Primary completion
- Oct 15, 2026
- Completion date
- Feb 15, 2027
- First posted
- Apr 3, 2024
- Last posted
- Sep 25, 2024
- Enrollment
- 76
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ajax Therapeutics, Inc.Lead sponsor
- Icahn School of Medicine at Mount SinaiOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.